Nuvilex (NASDAQ:PMCB) CEO Joshua Silverman Acquires 30,000 Shares

Nuvilex Inc. (NASDAQ:PMCB) CEO Joshua Silverman bought 30,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were bought at an average price of $0.78 per share, for a total transaction of $23,400.00. Following the transaction, the chief executive officer owned 346,250 shares of the company’s stock, valued at approximately $270,075. This represents a 9.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Joshua Silverman also recently made the following trade(s):

• On Wednesday, January 7th, Joshua Silverman purchased 40,000 shares of Nuvilex stock. The stock was bought at an average price of $0.83 per share, with a total value of $33,200.00.

Nuvilex Trading Up 7.5%

Shares of NASDAQ PMCB traded up $0.06 during mid-day trading on Wednesday, hitting $0.83. The company had a trading volume of 296,817 shares, compared to its average volume of 292,514. The stock’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.95. The company has a market capitalization of $8.41 million, a price-to-earnings ratio of -0.60 and a beta of 0.04. Nuvilex Inc. has a 1 year low of $0.63 and a 1 year high of $1.90.

Nuvilex (NASDAQ:PMCB) last issued its earnings results on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Nuvilex has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.